Axsome Therapeutics

At the Wells Fargo Healthcare Conference, Axsome reported a stronger commercial base driven by AUVELITY, whose annualized revenue at the end of Q2 was about $750 million and whose new prescriptions are rising sharply. The company had roughly $330 million in cash at the end of Q2 and is targeting positive cash flow, while sales investments in H2 2024 are expected to provide operational leverage. The launch of AUVELITY for Alzheimer-related agitation is underway and shows early demand in long-term inpatient care. The pipeline includes an NDA under FDA review for AXS-12 (PDUFA May 1, 2027) and several phase III programs (binge eating, shift work disorder, ADHD) that offer further growth potential. » Altro su de.investing.com

Axsome Therapeutics shares are up 16% year‑to‑date as Q2 revenue rose 46% to $218.4 million, driven by Auvelity net sales of $180.3 million and a recent FDA label expansion for Alzheimer's agitation. The company is advancing multiple mid/late‑stage programs—including AXS‑12 under regulatory review and trials for AXS‑14 and AXS‑20—and projects peak sales above $16 billion. Wall Street price targets imply further upside, though clinical, regulatory and competitive risks could derail forecasts. » Altro su finance.yahoo.com

ClearBridge Small Cap Growth Strategy added Axsome Therapeutics as a new position, citing its commercial-stage CNS focus and the large opportunity for its key drug Auvelity after approval in major depressive disorder and recent expansion into Alzheimer’s disease agitation. Axsome closed July 23 at $241.53 with a $12.43 billion market cap and has gained 139.54% over the past 52 weeks. The strategy delivered strong absolute returns in Q2 2026 but lagged the Russell 2000 Growth due to underweights in high-beta AI names and mixed performance in some healthcare holdings. » Altro su finance.yahoo.com